The U.S. Food and Drug Administration has once again declined to approve Aldeyra Therapeutics treatment for dry eye disease, ...

The topical ocular drug is an investigational new drug candidate that requires more well-controlled studies to establish ...

The FDA has set back Aldeyra Therapeutics’ ambitions to win approval for its dry eye disease, rejecting its second ...

The FDA issued a complete response letter for the resubmission of the reproxalap new drug application for the treatment of ...

FDA rejects Aldeyra's dry eye drug reproxalap again, seeks more data. Company plans 2025 resubmission. AbbVie partnership ...

Aldeyra Therapeutics shares fell 73% to $1.42 in the regular session after it reported a Food and Drug Administration complete response letter for reproxalap for treatment of dry eye disease. The ...

He is studying methazolamide, a treatment currently used to manage glaucoma, to find out if it can also help treat ...

Akums Drugs & Pharmaceuticals Ltd. on Tuesday announced the launch of a pioneering Ripasudil-Timolol combination therapy for ...

Drug-loaded contact lenses for glaucoma treatment appear to demonstrate safety and effectiveness in reducing IOP, according to a systematic review published in European Journal of Pharmacology. Drug-l ...

Opthea’s eye disease drug has failed its second phase 3 trial in a week, leaving the Australian biotech to discard the entire ...

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive ...